Latest Fairmouont Bancorp (FMTB) Headlines Mi
Post# of 4
Posted On: 03/09/2014 9:12:13 PM
Latest Fairmouont Bancorp (FMTB) Headlines
Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 13, 10:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/cmq2ml/pharmapoint) has announced the addition of the "PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022" report to their offering. The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. The base-year market leader in the US is Roche/Novartis' Lucentis, with $497m in sales, as the drug is the first-to-market anti-VEGF inhibitor approved for the treatment of DME. Lucentis will face stiff competition in Regeneron/Bayer's Eylea, which is currently in Phase III trials for DME. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 5.3 Diabetic Nephropathy: Product Profiles - Major Classes and Brands 5.4 Diabetic Retinopathy: Product Profiles - Major Classes and Brands 5.5 Diabetic Neuropathy: Product Profiles - Major Classes and Brands 6 Opportunity and Unmet Need 6.1 Overview 6.2 Unmet Needs 6.3 Unmet Needs Gap Analysis 6.4 Opportunity: Therapy for the Underlying Cause of the Microvascular Complications of Diabetes 6.5 Opportunity: Patient-Tailored Therapy for the Microvascular Complications of Diabetes 6.6 Opportunity: Efficacious Therapy for Diabetic Nephropathy 6.7 Opportunity: Topical Treatment for Diabetic Retinopathy 6.8 Opportunity: Treatment for Diabetic Neuropathy 7 Pipeline Assessment 7.1 Overview 7.2 Promising Drugs in Clinical Development 7.2.1 Eylea (aflibercept) 7.2.2 Optina (danazol) 7.2.3 Atrasentan Hydrochloride 7.2.4 Ranirestat 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/cm...harmapoint
10-Q: FAIRMOUNT BANCORP, INC.
Edgar Online - Thu Feb 13, 8:41AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 13, 10:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/cmq2ml/pharmapoint) has announced the addition of the "PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022" report to their offering. The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. The base-year market leader in the US is Roche/Novartis' Lucentis, with $497m in sales, as the drug is the first-to-market anti-VEGF inhibitor approved for the treatment of DME. Lucentis will face stiff competition in Regeneron/Bayer's Eylea, which is currently in Phase III trials for DME. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 5.3 Diabetic Nephropathy: Product Profiles - Major Classes and Brands 5.4 Diabetic Retinopathy: Product Profiles - Major Classes and Brands 5.5 Diabetic Neuropathy: Product Profiles - Major Classes and Brands 6 Opportunity and Unmet Need 6.1 Overview 6.2 Unmet Needs 6.3 Unmet Needs Gap Analysis 6.4 Opportunity: Therapy for the Underlying Cause of the Microvascular Complications of Diabetes 6.5 Opportunity: Patient-Tailored Therapy for the Microvascular Complications of Diabetes 6.6 Opportunity: Efficacious Therapy for Diabetic Nephropathy 6.7 Opportunity: Topical Treatment for Diabetic Retinopathy 6.8 Opportunity: Treatment for Diabetic Neuropathy 7 Pipeline Assessment 7.1 Overview 7.2 Promising Drugs in Clinical Development 7.2.1 Eylea (aflibercept) 7.2.2 Optina (danazol) 7.2.3 Atrasentan Hydrochloride 7.2.4 Ranirestat 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/cm...harmapoint
10-Q: FAIRMOUNT BANCORP, INC.
Edgar Online - Thu Feb 13, 8:41AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
(0)
(0)Fairmouont Bancorp (FMTB) Stock Research Links
Scroll down for more posts ▼